Camlin Fine Sciences Q1 FY27 Call Transcript Released
Camlin Fine Sciences released its Q1 FY27 earnings call transcript. Revenue increased 28% YoY to INR5,199 million, but margins were impacted by raw material costs. The company expects full-year revenue of INR2,000-2,400 crore and EBITDA margins of 10-12%. They anticipate returning to double-digit EBITDA by Q3 FY27.
The announcement provides an update on financial performance and future guidance, which is material for investors. However, it does not contain any major new corporate actions or significant deviations from prior expectations that would warrant a 'HIGH' impact.
The company reported revenue growth but faced margin pressures due to increased raw material and freight costs. While future outlook is cautiously optimistic, the immediate performance was mixed.
Camlin Fine Sciences Limited has released the transcript of their conference call held on August 11, 2026, discussing the Un-audited Financial Results for the quarter ended June 30, 2026. The management, including Chairman & Managing Director Mr. Ashish Dandekar, Managing Director Mr. Nirmal Momaya, and CFO Mr. Santosh Parab, presented the company's performance.
The company has transitioned to reporting financial figures in millions, moving away from the traditional lakhs and crores to align with international standards. They have also introduced segmental information, dividing the business into three verticals: Specialty Ingredients (formerly straights and blends), Aroma (vanillin and fragrance business), and Performance Chemicals (predominantly downstream of diphenol).
Overall revenues for the quarter stood at INR5,199 million, a 28% increase year-on-year. However, margins were impacted by rising raw material and freight costs. The Specialty Ingredients segment reported revenues exceeding INR4,000 million with an EBITDA of 6.35%, while the Aroma segment is expected to achieve positive EBITDA in the second quarter. The diphenol plant remains shut down due to economic reasons and high phenol prices, with the company procuring intermediates from China. Performance Chemicals also saw a negative EBITDA of 2.5% due to the diphenol plant closure but is projected to turn positive in the next quarter.
The company has guided for full-year revenue between INR2,000 crore and INR2,400 crore, with an expected EBITDA margin of 10% to 12%. They anticipate a return to double-digit EBITDA margins by the third quarter. The company's debt remains under control, with gross debt at INR640 crore as of the reporting period. They are also managing working capital challenges arising from global shipping disruptions and customer payment cycles.
What to do with a filing like this
Camlin Fine Sciences Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Camlin Fine Sciences Limited. Read the original for the full detail.